How Would the Authors Treat Their Own Temporary Left Ventricular Failure With Mechanical Circulatory Support?

J Cardiothorac Vasc Anesth. 2022 May;36(5):1238-1250. doi: 10.1053/j.jvca.2021.10.020. Epub 2021 Oct 21.

Abstract

In the last 20 years, mechanical circulatory supports (MCS) have overturned completely the outcomes and the clinical recovery of patients with isolated acute left ventricle failure (iALVF). This usually occurs more frequently than right-sided heart failure or biventricular dysfunction, and it mainly is caused by acute myocardial infarction. The primary role of MCS is to restore the tissue metabolism to preserve the vital organs' function but, on the other hand, they also have to relieve the workload stress on the heart. In this way, they allow not only the heart to recover from the acute event, but MCS also can stabilize the patient toward cardiac transplantation. The short-term MCS devices currently used in clinical practice are the intraaortic balloon pump, the Impella (Abiomed, Danvers, MA), and venoarterial extracorporeal membrane oxygenation (VA-ECMO), but the choice of the right and tailored device for each patient, as well as the timing to use it, is actually one of the most debated topics of MCS management.

Keywords: ECMO; IABP; Impella; left heart failure; mechanical circulatory support.

MeSH terms

  • Extracorporeal Membrane Oxygenation* / adverse effects
  • Heart Failure* / etiology
  • Heart Failure* / surgery
  • Heart Transplantation* / adverse effects
  • Heart-Assist Devices* / adverse effects
  • Humans
  • Intra-Aortic Balloon Pumping / adverse effects
  • Shock, Cardiogenic / etiology